Therapeutics News and Research

RSS

Mapping the brain’s serotonin switch could lead to better antidepressants

In a discovery that could guide the development of next-generation antidepressants and antipsychotic medications, researchers at the Icahn School of Medicine at Mount Sinai have developed new insights into how a critical brain receptor works at the molecular level and why that matters for mental health treatments.

1 Aug 2025

New study shows brain's role in diabetic ketoacidosis

More than a decade ago, researchers found that an acute complication of type 1 diabetes, diabetic ketoacidosis (DKA), can be resolved with the hormone leptin, even in the absence of insulin.

1 Aug 2025

Unlocking the power of stereochemistry to improve mRNA drug delivery

A team from the Max-Planck-Institut für Kohlenforschung, Hokkaido University, and Osaka University has discovered that subtle differences in molecular structure can have a major impact on the performance of mRNA-based drugs.

1 Aug 2025

Characterization of antibodies targeting ASO modifications for intracellular trafficking

A new article in the peer-reviewed journal Nucleic Acid Therapeutics describes the characterization of antibodies targeting antisense oligonucleotide (ASO) phosphorothioate and 2'-methoxyehtyl modifications for intracellular trafficking and biodistribution studies.

1 Aug 2025

Gut bacteria produce hormone-like proteins that regulate weight and blood sugar

Our intestines are home to trillions of microorganisms that produce substances capable of regulating all the body's organs via the bloodstream and the gut's nervous system.

31 Jul 2025

New treatment shows promise in protecting brain following stroke reperfusion

Cambridge scientists have developed and tested a new drug in mice that has the potential to reduce damage to the brain when blood flow is restored following a stroke.

31 Jul 2025

Promising treatment slows liver cancer by inhibiting fat enzyme

Liver cancer cells thrive on fat, posing a serious risk of cancer diagnosis for millions of people living with fatty liver disease.

31 Jul 2025

Experimental drug found to be safe and effective in treating children with MIS-C

In a small trial, Mass General Brigham researchers found a drug designed to treat Celiac disease supported a more rapid return to normal activities for patients following COVID.

30 Jul 2025

Promising new treatment helps the immune system attack and destroy liver tumors

Liver cancer cells thrive on fat, posing a serious risk of cancer diagnosis for millions of people living with fatty liver disease.

30 Jul 2025

Researchers classify how specific genetic mutations correspond to rare disorders

The NF-κB signaling pathway plays a pivotal role in how our bodies fight infection, heal, and regulate inflammation. At the heart of this pathway is the NEMO protein, encoded by the IKBKG gene.

30 Jul 2025

Rising liver cancer rates highlight need for urgent action worldwide

The majority of liver cancer cases could be prevented by reducing levels of viral hepatitis, alcohol consumption and MASLD (metabolic dysfunction-associated steatotic liver disease – previously called non-alcoholic fatty liver disease), suggests an analysis as part of The Lancet Commission on liver cancer.

29 Jul 2025

NR2F1 drives fibrotic cataract formation through activation of STAT3

Cataracts remain one of the most prevalent and debilitating eye conditions, often requiring surgical intervention to restore sight. Yet even after surgery, many patients develop anterior subcapsular cataracts (ASC), characterized by fibrotic tissue growth beneath the lens capsule.

29 Jul 2025

Pyruvate identified as a promising oral treatment for ulcerative colitis

Ulcerative colitis (UC) is a chronic inflammatory disease marked by intestinal pain, bleeding, and impaired gut barrier function.

29 Jul 2025

NKAPL identified as a tumor suppressor and therapeutic target in NSCLC

Non-small cell lung cancer (NSCLC) accounts for over 80% of lung cancer cases and is often diagnosed at advanced stages, limiting treatment options.

29 Jul 2025

Centauri Therapeutics receives an additional $5.1 M from CARB-X to progress ABX-01 lead compound to first in human clinical trials

Centauri Therapeutics Limited ('Centauri'), an immunotherapy company with a unique and proprietary platform technology applicable across a wide range of therapeutic indications, announced today that CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) has provided an additional $5.1 M in funding for the development of their lead compound.

29 Jul 2025

Exonate plans 'CLEAR-DE' Phase IIb clinical trial of lead candidate EXN407 for diabetic eye disease

Exonate Ltd., a biotechnology company developing novel, non-invasive, small-molecule therapeutics for patients with retinal vascular diseases, today announced plans to initiate a Phase IIb clinical trial for its lead candidate EXN407.

29 Jul 2025

Researchers map key mechanism for bladder function

Urinary incontinence is a devastating condition affecting over 33 million Americans, according to the National Association for Continence, leading to significant adverse impacts on patients' mental health and quality of life. Disorders of urination are also a key feature of all neurological disorders.

29 Jul 2025

New computer program mimics cell behavior for faster medical discoveries

Using mathematical analysis of patterns of human and animal cell behavior, scientists say they have developed a computer program that mimics the behavior of such cells in any part of the body.

28 Jul 2025

Marbling of fat inside muscles found to block healing and weaken strength

Consider the delicate web of fat in a Wagyu steak. The "marbling" that makes carnivore connoisseurs swoon is a visual heuristic for quality flavor.

28 Jul 2025

New model predicts mRNA protein production, accelerating drug and vaccine discovery

A new artificial intelligence model can improve the process of drug and vaccine discovery by predicting how efficiently specific mRNA sequences will produce proteins, both generally and in various cell types. The new advance, developed through an academic-industrial partnership between The University of Texas at Austin and Sanofi, helps predict how much protein cells will produce, which can minimize the need for trial-and-error experimentation, accelerating the next generation of mRNA therapeutics.

26 Jul 2025